Gary J. Doherty

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 28, 2026

Assessing contribution of effect in oncology combination therapies: lessons learned to inform and optimize future registrational trial designs.

Assessing contribution of effect in oncology combination therapies: lessons learned to inform and optimize future registrational trial designs.

Journal: The oncologist

Published: January 13, 2026

Assessing Contribution of Effect in Oncology Combination Therapies: Lessons Learned to Inform and Optimize Future Registrational Trial Designs.

Assessing Contribution of Effect in Oncology Combination Therapies: Lessons Learned to Inform and Optimize Future Registrational Trial Designs.

Journal: The oncologist

Published: January 13, 2026

Author Correction: The long-term effects of chemotherapy on normal blood cells.

Author Correction: The long-term effects of chemotherapy on normal blood cells.

Journal: Nature genetics

Published: July 31, 2025

Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers.

Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers.

Journal: Journal for immunotherapy of cancer

Published: April 29, 2025

Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study.

Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study.

Journal: British journal of clinical pharmacology

Published: March 12, 2025

Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC.

Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 10, 2025

Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome.

Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome.

Journal: Nature aging

Published: January 17, 2025

The long-term effects of chemotherapy on normal blood cells.

The long-term effects of chemotherapy on normal blood cells.

Journal: Nature genetics

Published: September 11, 2024

BMScope: A scoping review to chart the evolving clinical study landscape in brain and leptomeningeal metastasis.

BMScope: A scoping review to chart the evolving clinical study landscape in brain and leptomeningeal metastasis.

Journal: Neuro-oncology

Published: August 02, 2024

Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy.

Machine learning modeling of patient health signals informs long-term survival on immune checkpoint inhibitor therapy.

Journal: iScience

Published: April 12, 2024

Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer.

Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer.

Journal: Trends in cancer

Published: February 28, 2024

Showing 1-12 of 41

Last Updated: 09/26/2026